Roche Holding | ROG - Cash And Equivalent


Roche Holding reported CHF7.55B in Cash and Equivalent for its fiscal semester ending in June of 2025.





Cash And Equivalent Change Date
AbbVie USD 6.57B 2.82B Jun/2026
Alcon AG USD 1.58B 80M Mar/2026
Almirall EUR 337.77M 14.83M Dec/2025
Amgen USD 13.99B 1.95B Jun/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
Bayer EUR 4.29B 1.44B Jun/2026
Biogen USD 1.3B 18.9M Sep/2026
Bristol-Myers Squibb USD 9.57B 852M Sep/2026
Eli Lilly USD 4.89B 4.07B Sep/2026
Fresenius EUR 2.06B 752M Mar/2026
Fresenius Medical Care EUR 1.06B 177.89M Jun/2026
Genmab DKK 1.5B 18M Jun/2026
Gilead Sciences USD 3.18B 4.45B Jun/2026
GlaxoSmithKline GBP 3.1B 337M Jun/2026
GRIFOLS EUR 513M 189M Jun/2026
Hikma Pharmaceutical USD 217M 19M Dec/2025
Lakefront Biotherapeutics EUR 135.95M 69.15M Jun/2026
Lonza CHF 719M 188M Dec/2025
Merck EUR 2.74B 415M Mar/2026
Merck USD 6.85B 1.52B Jun/2026
Novartis USD 7.62B 739M Jun/2026
Orion EUR 144.3M 55M Sep/2026
Pfizer USD 976M 727M Jun/2026
Philips EUR 1.79B 803M Jun/2026
Recordati EUR 391.38M 10.92M Jun/2026
Regeneron Pharmaceuticals USD 3.66B 1.2B Sep/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 6.35B 806M Jun/2026
UCB EUR 1.57B 1.14B Dec/2024